NeoGenomics, Inc. is a cancer diagnostics and pharma services company headquartered in Fort Myers, Florida. The company operates a network of CAP-accredited and CLIA-certified laboratories across the United States and the United Kingdom, providing comprehensive oncology-focused testing services. NeoGenomics operates through two primary business segments: Clinical Services and Pharma Services. The Clinical Services segment, which generates the vast majority of the company's revenue, provides cancer-related diagnostic testing—such as next-generation sequencing (NGS), flow cytometry, and fluorescence in-situ hybridization (FISH)—to community-based pathologists, oncologists, and hospitals. The Pharma Services segment supports pharmaceutical companies in their drug development programs and clinical trials by offering specialized testing to identify patient populations for targeted therapies. By focusing exclusively on oncology, NeoGenomics maintains a competitive position as a specialized diagnostic partner for community healthcare settings, where the majority of cancer patients receive care.
